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The endoplasmic reticulum (ER) is the cellular organelle
responsible for protein folding and assembly, lipid and
sterol biosynthesis, and calcium storage. The unfolded
protein response (UPR) is an adaptive intracellular
stress response to accumulation of unfolded or misfolded
proteins in the ER. In this study, we show that the most
conserved UPR sensor inositol-requiring enzyme 1 a
(IRE1a), an ER transmembrane protein kinase/endoribo-
nuclease, is required to maintain hepatic lipid homeostasis
under ER stress conditions through repressing hepatic
lipid accumulation and maintaining lipoprotein secretion.
To elucidate physiological roles of IRE1a-mediated signal-
ling in the liver, we generated hepatocyte-specific
Ire1a-null mice by utilizing an albumin promoter-
controlled Cre recombinase-mediated deletion. Deletion
of Ire1a caused defective induction of genes encoding
functions in ER-to-Golgi protein transport, oxidative
protein folding, and ER-associated degradation (ERAD)
of misfolded proteins, and led to selective induction of
pro-apoptotic UPR trans-activators. We show that IRE1a is
required to maintain the secretion efficiency of selective
proteins. In the absence of ER stress, mice with hepato-
cyte-specific Ire1a deletion displayed modest hepato-
steatosis that became profound after induction of ER
stress. Further investigation revealed that IRE1a represses
expression of key metabolic transcriptional regulators,
including CCAAT/enhancer-binding protein (C/EBP) b,
C/EBPd, peroxisome proliferator-activated receptor c
(PPARc), and enzymes involved in triglyceride bio-
synthesis. IRE1a was also found to be required for efficient
secretion of apolipoproteins upon disruption of ER homeo-
stasis. Consistent with a role for IRE1a in preventing
intracellular lipid accumulation, mice with hepatocyte-
specific deletion of Ire1a developed severe hepatic steatosis
after treatment with an ER stress-inducing anti-cancer
drug Bortezomib, upon expression of a misfolding-prone
human blood clotting factor VIII, or after partial hepatec-
tomy. The identification of IRE1a as a key regulator to
prevent hepatic steatosis provides novel insights into ER
stress mechanisms in fatty liver diseases associated with
toxic liver injuries.
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Introduction
Hepatosteatosis, characterized by excessive accumulation of
triglycerides (TGs) in hepatocytes, is considered the key meta-
bolic component of non-alcoholic fatty liver disease (NAFLD).
Hepatic lipid accumulation is regulated by a complex net-
work that involves lipogenesis, dietary fatty acid (FA) uptake,
FA oxidation, and lipid transport/secretion (Musso et al,
2009). Hepatic steatosis is the result of abnormal lipid
metabolism caused by increased lipid delivery to the liver,
increased de novo lipid biosynthesis, reduced lipid oxidation,
and/or decreased lipid secretion (Postic and Girard, 2008;
Musso et al, 2009). Although significant progress has been
made in understanding the metabolic pathways associated
with hepatosteatosis, the molecular signal transduction
network that triggers hepatic lipid dysregulation remains to
be identified. Recent findings suggest that intracellular stress
response pathways from the endoplasmic reticulum (ER) have
important roles in regulating expression of lipogenic factors,
secretion of apolipoproteins, lipid accumulation, and lipotoxi-
city (Scheuner et al, 2001; Feng et al, 2003; Wei et al, 2006;
Zhang et al, 2006a; Lee et al, 2008; Ota et al, 2008; Oyadomari
et al, 2008; Rutkowski et al, 2008). This has raised an important
notion that the ER stress response is an underlying mechanism
governing the development of hepatosteatosis.
The ER is the site for folding of membrane and secreted
proteins, synthesis of lipids and sterols, and storage of
calcium in eukaryotic cells. A number of biological, physio-
logical, or pathological stimuli can perturb protein folding in
the ER, leading to accumulation of unfolded or misfolded
proteins in the ER lumen—a condition referred to as ‘ER
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stress’ (Kaufman, 1999). To deal with ER stress conditions,
the ER has evolved a set of signal transduction pathways
collectively termed the unfolded protein response (UPR) to
alter transcriptional and translational programs in the stressed
cell. In metazoans, there are three basic signal transducers
of the UPR, inositol-requiring 1 (IRE1), PERK (double-strand
RNA-activated protein kinase-like ER kinase), and ATF6
(activating transcription factor 6). The most conserved UPR
transducer is IRE1, an ER transmembrane Ser/Thr protein
kinase/endoribonuclease that was originally identified as
the proximal sensor for the UPR in budding yeast (Nikawa
and Yamashita, 1992; Cox et al, 1993; Mori et al, 1993). The
IRE1-mediated UPR signalling pathway is highly conserved in
all eukaryotes. Two homologues of yeast ire1, Ire1a and Ire1b,
were identified in both the murine and human genomes
(Tirasophon et al, 1998; Wang et al, 1998). In mammals,
IRE1a is expressed in most cells and tissues, while IRE1b
expression is primarily restricted to intestinal epithelial
cells. The mRNA encoding X-box-binding protein 1 (XBP1),
a basic-leucine zipper (b-ZIP)-containing transcription factor,
was identified as an RNA substrate for the mammalian
IRE1a endoribonuclease activity (Shen et al, 2001; Yoshida
et al, 2001; Calfon et al, 2002). Upon activation of the
UPR, IRE1a initiates unconventional splicing of the Xbp1
mRNA to remove a 26-nucleotide intron and generate a
switch in translational-reading frame. Spliced Xbp1 mRNA
encodes a potent transcriptional activator that induces
transcription of genes encoding functions that facilitate
protein folding, secretion, and degradation in response to
ER stress.
In addition to functions that are strictly involved in protein
folding, trafficking, secretion, and degradation, the UPR is
now recognized to have important physiological roles in
metabolism, inflammation, as well as cell differentiation
and survival (Ron and Walter, 2007; Todd et al, 2008;
Zhang and Kaufman, 2008a). IRE1a and its endoribonuclease
target Xbp1 mRNA are required for the differentiation and
function of specialized cell types, and have been proposed to
contribute to the pathogenesis of metabolic disease (Reimold
et al, 2001; Zhang et al, 2005; Ron and Walter, 2007). Under
conditions of ER stress, activated IRE1a can bind to tumour
necrosis factor-receptor-associated factor 2 (TRAF2), leading
to activation of c-JUN N-terminal kinase (JNK) through
apoptosis signal-regulating kinase 1 (Urano et al, 2000;
Nishitoh et al, 2002). This might provide stressed cells with
survival or death signals by activating JNK-mediated signal-
ling pathways. Additionally, the cytosolic domain of IRE1a
can also recruit the pro-apoptotic BCL-2-associated X protein
and BCL-2 antagonist, augmenting both the kinase and en-
doribonuclease activities of IRE1a (Hetz et al, 2006). In the
liver, ER stress and UPR signalling can be triggered by
metabolic factors, such as lipids, glucose, cytokines, homo-
cysteine, and free FAs (Zhang and Kaufman, 2008a). In this
study, we generated hepatocyte-specific Ire1a-null mice.
Using this animal model, we show that IRE1a is essential to
maintain hepatic lipid homeostasis under conditions of ER
stress in the liver. Deletion of the Ire1a gene results in
profound hepatosteatosis and hypolipidemia in the mice
upon ER stress. The identification of a key role of IRE1a in
preventing ER stress-induced hepatosteatosis provides novel
insights into potential avenues to limit hepatic lipid accumu-
lation that contribute to metabolic syndrome.
Results
Hepatocyte-specific deletion of Ire1a is efficient
Homozygous Ire1a-null (Ire1a/) murine embryos die by
embryonic day 12.5, while the heterozygous Ire1aþ / mice
can survive as normal wild-type mice (Lee et al, 2002; Zhang
et al, 2005). The most significant phenotype of whole body
Ire1a deletion, as well as Xbp1 deletion, was liver hypoplasis
(Reimold et al, 2000; Zhang et al, 2005). In order to study the
tissue-specific and temporal roles of IRE1a in the mouse, we
engineered mice with a loxP site-flanked Ire1a allele (Ire1afe)
(Figure 1A and B) (Hoess and Abremski, 1990). Mice with
one or two floxed Ire1a alleles were viable, fertile, and
apparently normal. Mice that harbour one floxed Ire1a allele
and one Ire1a-null allele (Ire1afe/) were bred with transgenic
mice expressing Cre recombinase under the control of the
albumin promoter (Postic and Magnuson, 2000) to obtain
offspring with hepatocyte-specific Ire1a deletion (Ire1afe/
Creþ , herein called Ire1aHepfe/) and littermate control mice
(Ire1afe/þCreþ , herein called Ire1aHepfe/þ ) that have a func-
tional Ire1a allele. Functional deletion of Ire1a was evidenced
by the absence of spliced Xbp1 mRNA, the target of IRE1a
endoribonuclease activity, in the livers of the Ire1aHepfe/
mice challenged with a sublethal injection of tunicamycin
(TM), an inhibitor of N-linked glycosylation that causes
accumulation of misfolded protein in the ER (Figure 1C). In
comparison, significant levels of spliced Xbp1 mRNA were
detected in the control Ire1aHepfe/þ mice that harbour a
wild-type Ire1a allele. We have not observed a difference in
liver function between wild-type Ire1aþ /þ and our experi-
mental control Ire1aHepfe/þ mice (data not shown). Mice with
hepatocyte-specific Ire1a deletion (Ire1aHepfe/) were viable
and displayed no gross developmental or morphological
defects (Figure 1D). Although livers from Ire1aHepfe/ mice
appeared phenotypically normal in the absence of challenge,
ultrastructural analysis revealed less rough ER content in the
Ire1a-null (Ire1aHepfe/) livers, compared with the littermate
control (Ire1aHepfe/þ ) livers (Figure 1E), suggesting a possible
ER defect in the absence of IRE1a.
To characterize the phenotype of hepatocyte-specific
Ire1a deletion as well as the molecular targets of IRE1a in
the liver, we performed Affymetrix GeneChip microarray
analysis using total liver mRNA from Ire1aHepfe/ and control
Ire1aHepfe/þ mice injected with TM (2 mg/g body weight)
induce acute ER stress in the liver (Zhang et al, 2006a).
Surprisingly, deletion of Ire1a caused only a slight alteration
in gene expression in the absence of stress. Upon close
analysis, we identified a subset of genes with reduced or
increased expression that encoded functions associated with
ER signal transduction and lipid metabolism (Figure 2A)
(Table I) (Supplementary Figure S1A and B). However, at
8 h after TM injection, the RNA expression profile in the
Ire1aHepfe/ liver was significantly altered, compared with
that characterized in the livers of control Ire1aHepfe/þ mice
(Figure 2A). The microarray results indicated that IRE1a is
required for ER stress-mediated induction of genes involved
in ER function, intracellular stress responses, lipid metabo-
lism, cell differentiation, alternative mRNA splicing, and
signal transduction (Figure 2B) (Table I). Quantitative real-
time PCR analyses confirmed that IRE1a is required for
ER stress-induced expression of genes encoding functions
in ER-to-Golgi protein transport (Sec22l1, Sec61a1, Sec24d,
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Tmed3), protein folding such as cis–trans proline isomeriza-
tion and disulfide bond formation (Fkbp11, Pdi4, Ero1a,
Ero1lb, P58IPK), and ER-associated degradation (ERAD)
(Edem1, Hrd1, Erdj4, Erdj3) (Figure 2C). These results
support the hypothesis that IRE1a is required to maintain
ER function and remodel the secretory apparatus in response
to protein misfolding in the ER.
Deletion of Ire1a causes UPR activation and defective
adaptation to ER stress
Next, we asked whether Ire1a deletion in hepatocytes alters
ER homeostasis and activates the other UPR signalling
pathways. To address this question, we first compared
the expression of the ER chaperones GRP78/BiP and
GRP94, two markers of the ER stress response, in the livers
from hepatocyte-specific Ire1a-null (Ire1aHepfe/) and control
(Ire1aHepfe/þ ) mice after intraperitoneal injection of vehicle
or TM. Expression of GRP78 and GRP94 in the Ire1a-deleted
livers was modestly decreased compared with control livers
from 8 to 72 h after TM treatment (Figure 3A). In comparison,
the expression of ER stress-inducible pro-apoptotic transcrip-
tion factors ATF4 (activating factor 4), CHOP (CCAAT/
enhancer-binding protein (C/EBP) homologous transcription
factor), and ATF3 (activating factor 3) was significantly
increased in the Ire1a-null livers compared with the control
livers at 8–72 h after TM treatment (Figure 3A). Because
ATF4, CHOP, and ATF3 were documented to be upregulated
by the PERK/eIF2a subpathway of the UPR (Harding et al,
2000; Scheuner et al, 2001; Wek et al, 2006), we thought that
the PERK UPR pathway may be activated by Ire1a deletion
in hepatocytes. Although we failed to detect a significant
increase in phosphorylation of PERK, phosphorylation of
eIF2a was increased at the early time points in the
Ire1a-null livers, compared with that in the control livers
(Figure 3B). Furthermore, levels of the growth arrest and
DNA damage-inducible protein 34 (GADD34), a PERK/eIF2a-
regulated stress protein that has a feedback regulatory role by
dephosphorylating eIF2a (Novoa et al, 2001), were higher in
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Figure 1 Hepatocyte-specific deletion of Ire1a. (A) Schematic illustration of the targeting vector and the Ire1a-null alleles. The targeting vector
contained loxP-flanked exons 16 and 17 of the murine Ire1a gene as well as a loxP-flanked Neomycin (Neo) cassette. The engineered mice
containing the targeted allele were backcrossed with ZP3-Cre transgenic mice in order to generate mice with the loxP-flanked Ire1a allele
without the Neo cassette. This mouse strain was then crossed with heterozygous Ire1a-null mice (Lee et al, 2002; Zhang et al, 2005) to produce
mice containing an Ire1a conditional allele (Ire1afe) and an Ire1a-null allele (Ire1a). (B) Genotyping of conditional Ire1a-null mice. Mice
harbouring a conditional Ire1a allele in the presence of an Ire1a-null or wild-type allele were crossed with transgenic mice that express Cre
recombinase under the control of the albumin promoter to generate hepatocyte-specific Ire1a-null mice (Ire1aHepfe/) and control mice that
harbour a functional Ire1a allele (Ire1aHepfe/þ ). Three pairs of PCR reactions were used for genotyping: one pair amplifies the targeted allele
and the wild-type allele; a second pair amplifies the Neo cassette to identify the Ire1a-null allele (Lee et al, 2002; Zhang et al, 2005); and a third
set amplifies the Cre transgene. (C) Semiquantitative reverse transcription (RT)–PCR of Xbp1 mRNA. Xbp1 mRNA splicing was not detected in
livers of hepatocyte-specific Ire1a-null mice (Ire1aHepfe/) at 8 h after intraperitoneal injection of TM (2mg/g body weight). (D, E) Liver sections
from hepatocyte-specific Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice in the absence of TM challenge stained with haematoxylin and
eosin (magnification  200) (D) and transmission electron microscopy (magnification  19 000) (E).
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the Ire1a-null livers at the early time points (0–24 h) after TM
injection but comparable to that in the control livers at later
time points (36–72 h) after TM injection (Figure 3A). It is
possible that the induction of GADD34 causes dephos-
phorylation of eIF2a and PERK. These data suggest that
Ire1a deletion in the liver leads to selective upregulation of
ER stress-inducible pro-apoptotic factors ATF4, CHOP, and
ATF3. This selective upregulation may reflect a defect in the
ability of Ire1a-null livers to adapt to ER stress, as levels
of cleaved caspase-3, the cell apoptosis executioner, and
positive terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labelling (TUNEL) staining were
increased in the Ire1a-null livers after TM treatment (Figure
3A and D). Analysis of ATF6 cleavage indicated that it was
increased in the Ire1aHepfe/ livers compared with the
Ire1aHepfe/þ livers, after TM challenge (Figure 3C), suggesting
that Ire1a deletion also upregulates the ATF6 branch of the
UPR in response to ER stress. Because IRE1a/XBP1 and ATF6
have redundant roles in activating expression of ER chaper-
ones and protein-folding enzymes (Okada et al, 2002; Lee
et al, 2003b; Wu et al, 2007), increased cleavage of ATF6 in
Ire1a-null livers may compensate, at least partially, for the
defect caused by Ire1a deletion in activating expression of
UPR target genes.
To further evaluate the ability of Ire1a-null hepatocytes
to adapt to prolonged ER stress, we treated immortalized
Ire1a-null (Ire1afe/Cre) and control (Ire1afe/fe) hepato-
cytes with TM for up to 24 h in vitro. In response to TM,
expression of ER stress-induced pro-apoptotic factor CHOP
was significantly different between the Ire1a-null and
control hepatocytes (Figure 3E). Although the Ire1a-null
and control hepatocytes expressed similar levels of CHOP
in the absence or presence of TM for up to 3 h, CHOP
expression in the Ire1a-null hepatocytes was significantly
greater than that in the control hepatocytes from 9 to 24 h
after TM treatment (Figure 3E). CHOP expression in the
control hepatocytes was induced from 3 to 9 h of TM
treatment, but was subsequently attenuated, suggesting
that the control hepatocytes adapted to ER stress at the
later time points of TM treatment. In contrast, the Ire1a-
null hepatocytes sustained high levels of CHOP expression
up to 24 h after TM treatment (Figure 3E), suggesting the
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Figure 2 IRE1a regulates expression of genes involved in protein folding, ER-to-Golgi transport, and ERAD. (A) Affymetrix microarray analysis
of mRNA expression profiles in livers of Ire1aHepfe/ and Ire1aHepfe/þ mice at 3 months of age at 8 h after intraperitoneal injection of TM (2mg/g
body weight) or vehicle (150 mM dextrose). Graphic representation of ANOVA analysis is shown for the expression of 177 genes (P-value cutoff
was o0.05) that were significantly regulated upon TM injection into control mice (Ire1aHepfe/þ ). Each vertical bar represents a single gene.
Blue indicates lower expression and red indicates higher expression. (B) Percentages of IRE1a-regulated TM-inducible genes. The 177 TM-
regulated genes identified by ANOVA were clustered based on their functions. The percentages of biological pathway-specific gene groups that
are regulated by IRE1a are shown. (C) Quantitative real-time RT–PCR analysis of liver mRNA isolated from Ire1aHepfe/ and Ire1aHepfe/þ mice.
Total liver mRNA was isolated at 8 h after injection with vehicle or TM (2 mg/g body weight) for real-time RT–PCR analysis. Expression values
were normalized to b-actin mRNA levels. Fold changes of mRNA are shown in TM-treated mice compared with control mice. Each bar denotes
the mean±s.e.m. (n¼ 6 mice per group); *Po0.05, **Po0.01. P-values are shown for statistically significant differences. Edem1, ER
degradation enhancing, mannosidase a-like 1; Sec22l1, SEC22 vesicle trafficking protein-like 1; Sec61a1, Sec61 a 1 subunit; Sec24d, SEC24-
related gene family, member D; Tmed3, transmembrane emp24 domain containing 3; Pdi4, protein disulfide isomerase associated 4; Fkbp11,
FK506-binding protein 11 of the peptidyl-prolyl cis–trans isomerase family; ERo1a, ER oxidoreductase-1 a, ERo1lb, ERO1-like b; Hrd1, or Syvn1,
synovial apoptosis inhibitor 1; ERdj4, DnaJ (Hsp40) homologue, subfamily B, member 9; ERdj3, DnaJ (Hsp40) homologue, subfamily B,
member 11; P58(IPK), or Dnajc3, DnaJ (Hsp40) homologue, subfamily C, member 3.
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Table I List of genes regulated by IRE1a in response to TM treatment
Name Description Expression levels TM induction
Genbank CTL KO CTL-TM KO-TM KO/CTL (%)
Endoplasmic reticulum function
Syvn1 Synovial apoptosis inhibitor 1 AK004688 0.26±0.04 0.26±0.06 4.21±0.22 2.14±0.44 50.89
Slc35b1 Solute carrier family 35, member B1 NM_016752 0.45±0.05 0.34±0.06 2.88±0.17 1.69±0.23 58.69
Surf4 Surfeit gene 4 AW990392 1.04±0.08 0.89±0.04 2.57±0.12 0.96±0.07 37.34
Piga Phosphatidylinositol glycan, class A AV340508 0.23±0.07 0.25±0.02 2.93±0.21 1.87±0.23 63.33
Spcs2 Signal peptidase complex subunit 2 homologue BI078449 0.89±0.07 0.63±0.05 2.48±0.17 1.09±0.06 43.76
Sel1h Sel1 (suppressor of lin-12) 1 homologue BC026816 0.52±0.06 0.43±0.07 2.06±0.09 1.56±0.13 75.97
Sdf2l1 Stromal cell-derived factor 2-like 1 NM_022324 0.16±0.04 0.12±0.02 2.82±0.31 2.0±0.20 70.98
Wfs1 Wolfram syndrome 1 homologue NM_011716 0.45±0.04 0.39±0.09 4.86±0.46 1.69±0.32 34.81
Srpr Signal recognition particle receptor BC021839 0.95±0.03 0.86±0.07 2.09±0.15 1.03±0.01 49.26
Lepre1 Leprecan 1 BE283629 0.88±0.14 0.84±0.10 5.03±0.69 1.08±0.15 21.42
Sec11l1 Sec11-like 1 BG919982 0.60±0.03 0.55±0.01 2.17±0.05 1.39±0.02 63.89
Ssr3 Signal sequence receptor, g AU022074 0.90±0.06 0.80±0.09 2.49±0.12 1.11±0.06 44.65
Edem1 ER degradation enhancer, mannosidase a 1 BG064496 0.63±0.05 0.53±0.08 2.43±0.16 1.38±0.05 56.84
Molecular chaperone, stress response
Ckap1 Cytoskeleton-associated protein 1 NM_025548 0.45±0.08 0.44±0.01 2.37±0.21 1.65±0.21 69.63
Dnajb11 DnaJ (Hsp40) homologue, subfamily B,
member 11
AK010861 0.35±0.06 0.29±0.06 2.28±0.21 1.66±0.07 72.78
Dnajc3 DnaJ (Hsp40) homologue, subfamily C,
member 3
BE624323 0.53±0.06 0.42±0.04 3.96±0.33 1.69±0.26 42.56
Pdrg1 p53 and DNA damage regulated 1 AK003410 0.73±0.05 0.76±0.05 1.91±0.05 1.31±0.11 68.75
Oxidative protein folding, oxireductase
Ero1l ERO1-like BM234652 0.63±0.09 0.63±0.03 3.08±0.45 1.52±0.20 49.38
Ero1lb ERO1-like b BB234316 0.41±0.01 0.35±0.01 2.62±0.08 1.83±0.25 70.1
ER-golgi protein transport
Tmed3* Transmembrane emp24 domain containing 3 NM_025360 0.71±0.14 0.45±0.07 6.03±0.49 1.27±0.23 21.15
MGI:1929095 Vesicle docking protein BC016069 0.73±0.07 0.57±0.02 2.98±0.22 1.36±0.14 44.78
Golga3 Golgi autoantigen, golgin subfamily a, 3 D78270 0.80±0.03 0.81±0.02 2.76±0.13 1.23±0.10 44.62
Sec22l1 SEC22 vesicle trafficking protein-like 1 BC009024 0.76±0.10 0.71±0.11 3.35±0.32 1.16±0.043 34.63
Sec61a1 Sec61 a 1 subunit BC003707 0.87±0.05 0.75±0.04 2.84±0.14 1.14±0.07 40.2
Slc35b1 solute carrier family 35, member B1 NM_016752 0.45±0.05 0.34±0.05 2.88±0.17 1.69±0.23 58.69
Sec24d SEC24 related gene family, member D AK009425 0.83±0.08 0.74±0.11 3.24±0.23 1.14±0.04 35.1
MGI:1929095 Vesicle docking protein BC016069 0.73±0.07 0.57±0.02 2.98±0.22 1.34±0.14 44.78
Stx5a Syntaxin 5A AU014962 0.70±0.03 0.65±0.02 3.66±0.17 1.32±0.07 36.16
Slc20a1 Solute carrier family 20, member 1 NM_015747 0.26±0.09 0.30±0.06 3.06±0.08 1.77±0.15 57.73
Slc25a28 Solute carrier family 25, member 28 BC025908 0.66±0.05 0.69±0.08 2.21±0.17 1.29±0.07 58.2
Cell differentiation
Hook1 Hook homologue 1 (Drosophila) BB463518 0.95±0.04 0.79±0.04 1.94±0.05 1.06±0.04 54.61
Gdf15* Growth differentiation factor 15 NM_011819 0.25±0.06 0.18±0.02 2.17±0.58 3.74±0.96 172.13
Ligase
Cad* Carbamoyl-phosphate synthetase 2 AK010453 0.34±0.06 0.53±0.07 5.31±0.52 1.88±0.461 35.44
Nars Asparaginyl-tRNA synthetase AK013880 0.66±0.04 0.65±0.06 1.83±0.14 1.32±0.02 71.82
Wars Tryptophanyl-tRNA synthetase AI528863 0.32±0.02 0.37±0.05 2.98±0.22 1.85±0.23 61.95
Lipid metabolism
Mvd* Mevalonate (diphospho) decarboxylase NM_138656 0.83±0.03 0.41±0.06 5.73±0.41 1.44±0.29 25.11
Gnat2 Guanine nucleotide binding protein NM_00814 0.44±0.10 0.33±0.04 11.71±0.86 1.64±0.18 18.68
Osbp Oxysterol binding protein BC003443 0.63±0.08 0.55±0.01 2.66±0.11 1.39±0.10 52.25
Arf4 ADP-ribosylation factor 4 BI653265 0.87±0.04 0.77±0.05 2.15±0.14 1.11±0.02 51.72
Hdlbp High-density lipoprotein (HDL) binding protein BG065877 0.81±0.01 0.76±0.04 1.95±0.11 1.28±0.09 65.52
Signal transduction
Srp68 Signal recognition particle 68 AI326252 0.82±0.05 0.83±0.04 2.53±0.18 1.19±0.09 47.08
Srp19 Signal recognition particle 19 W08076 0.88±0.07 0.80±0.10 2.59±0.14 1.10±0.05 42.45
Srpr Signal recognition particle receptor BC021839 0.95±0.03 0.86±0.07 2.09±0.15 1.03±0.01 49.26
Atp2a2 ATPase, Ca++ transport NM_00972 0.45±0.09 0.50±0.03 2.28±0.24 1.75±0.29 69.17
Gp1bb Glycoprotein 1b AF033350 0.44±0.14 0.36±0.07 15.83±5.36 1.62±0.19 12.51
Transcription regulation
Morf4l2 Mortality factor 4 like 2 BB068032 0.83±0.06 0.75±0.09 2.25±0.13 1.16±0.06 51.55
Hlf Hepatic leukemia factor BB744589 1.08±0.02 1.18±0.26 0.23±0.02 0.96±0.07 382.1
Smarcb1 SWI related, chromatin regulator BB820473 0.01±0.00 0.02±0.01 4.50±0.70 3.12±1.19 69.22
Creb3l2 cAMP responsive element binding
protein 3-like 2
AV021105 0.53±0.14 0.43±0.05 3.90±0.48 1.54±0.23 48.64
The expression levels were indicated by normalized average expression values obtained through microarray. The table displays the genes
whose expression was decreased or increased at least 1.5-fold in Ire1a-null liver, compared with the control, in response to TM treatment.
Po0.05. The right column indicates ratios of KO versus CTL in TM-induced fold changes of gene expression. The genes whose expression was
significantly different between knockout and control mice (without TM) was marked with an asterisk. CTL, control livers; KO, Ire1a-knockout
livers.
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Hepatocyte-specific Ire1a deletion increases hepatic
lipid and reduces plasma lipid content upon ER stress
Having established a role for IRE1a in the chronic response to
ER stress, we next investigated the physiological role of IRE1a
in the liver. In hepatocytes, TG are synthesized in the ER and
stored in the cytoplasm surrounded by a monolayer of
phospholipid in distinct lipid droplet structures (Martin and
Parton, 2006). Although no morphological or developmental
defects were observed in the hepatocyte-specific conditional
Ire1a-null (Ire1aHepfe/) mice, Oil-red O staining of liver tissue
sections revealed a slight increase in lipid content in livers
from the Ire1aHepfe/ mice (Figure 4A). Under normal physio-
logical conditions, lipid droplets maintain energy balance at
the cellular and organismal levels. As a response to acute
liver injury induced by sublethal doses of TM, lipid deposi-
tion is increased in the hepatocytes of wild-type mice
(Yang et al, 2007; Rutkowski et al, 2008). To test the role of
IRE1a in hepatic lipid accumulation in response to ER stress,
we injected Ire1aHepfe/ and control Ire1aHepfe/þ mice with
a dose of TM that can induce strong ER stress in the liver
in vivo (Zhang et al, 2006a; Wu et al, 2007). At 24 h after TM
injection, the livers from control mice displayed modest
macrovesicular steatosis characterized by engorgement
of the hepatocytes with larger lipid droplets (Figure 4B).
In contrast, in the livers of Ire1aHepfe/ mice, TM injection
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Figure 3 Ire1a deletion leads to upregulation of selective UPR genes in response to ER stress. (A–C) Xbp1 mRNA splicing and western blot
analysis of livers from Ire1aHepfe/ and Ire1aHepfe/þ mice at 3 months of age after intraperitoneal injection of TM (2mg/g body weight) for 8, 24,
36, 48, and 72 h. Mice injected with the vehicle (150mM dextrose) were included as the control time point 0. (A) Semiquantitative RT–PCR analysis
of Xbp1 mRNA splicing and western blot analysis of GRP94, GRP78/BiP, ATF4, ATF3, CHOP, GADD34, and caspase-3. Levels of a-tubulin were
included as internal controls. The values below the gels represent protein signal intensities that were quantified using NIH ImageJ software and
normalized to a-tubulin. (B, C) Western blot analysis of phosphorylated PERK, phosphorylated eIF2a, and ATF6. The values below the gels
represent normalized protein signal intensities. (D) Immunofluorescence TUNEL staining of liver tissue sections for DNA fragmentation. Liver
tissue sections were prepared from the Ire1aHepfe/ and Ire1aHepfe/þ mice after intraperitoneal injection of TM (2 mg/g body weight) for 36 h for
TUNEL staining. The green fluorescence represents TUNEL-positive and red fluorescence represents propidium iodide (PI)-positive cells
(magnification  400). The right panel shows the percentages of TUNEL-positive cells determined by calculating the number of TUNEL-
positive cells divided by the number of PI-positive cells from five fields of each slide. *Po0.05. (E) Western blot analysis of GRP94 and CHOP in
immortalized Ire1a-null (Ire1afe/Cre) and control (Ire1afe/fe) hepatocytes challenged with TM (2mg/ml) for indicated times. Ire1a-null and
control hepatocytes cultured in the absence of TM (at 0 and 24 h) were included as controls. Levels of GAPDH protein were determined as
internal controls. The values below the gels represent protein signal intensities after normalization to GAPDH. C, control hepatocytes; K, Ire1a-
null hepatocytes.
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the presence of small lipid droplets that surround the nucleus
(Figure 4B). At 72 h after TM injection, hepatic steatosis in
the control Ire1aHepfe/þ mice was significantly resolved, as
only small amounts of lipid droplets were detected in their
livers (Figure 4C). In contrast, the Ire1a-null livers remained
steatotic at 72 h after TM treatment, suggesting a role for
IRE1a in preventing and recovering from ER stress-induced
hepatic steatosis. Interestingly, at 72 h after TM treatment,
Ire1a-null livers displayed macrovesicular steatosis instead of
microvesicular steatosis that occurred at 24 h after TM treat-
ment. This suggests that the formation of larger lipid droplets
may be delayed in the Ire1a-null livers under conditions of ER
stress. To further analyse the phenotype caused by Ire1a
deletion at the subcellular level, ultrastructural analysis of
liver sections was performed. In response to TM treatment,
hepatocytes in the livers from Ire1aHepfe/ mice displayed
significantly more lipid droplets surrounding the nucleus,
compared with the livers from TM-injected control
Ire1aHepfe/þ mice (Figure 4D). Taken together, these obser-
vations indicate that IRE1a is required to minimize lipid
accumulation in response to acute ER stress.
Analysis of plasma lipid profiles demonstrated that
the levels of low-density lipoproteins (LDLs) and TG were
reduced by 28–55% in Ire1aHepfe/ mice, compared with that
in control Ire1aHepfe/þ mice (Figure 4E). The reduction in
plasma lipid contents became more profound in Ire1aHepfe/
mice at 8 h after TM injection compared with control mice
(Figure 4E). Analysis of the major lipid classes in the liver
demonstrated that hepatocyte-specific Ire1a deletion in-
creased cellular TG levels modestly in the absence of TM,
and more significantly at 8 h after TM injection (Figure 4F).
At 24 h after TM injection, the liver TG content in Ire1aHepfe/
mice continued to increase where TG levels were approxi-
mately six times greater than those observed in the livers
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Figure 4 Hepatocyte-specific Ire1a deletion leads to hepatosteatosis and reduced plasma lipids. Ire1aHepfe/ and Ire1aHepfe/þ mice at 3 months
of age were injected with TM (2 mg/g body weight) or vehicle (150 mM dextrose). At 8, 24, and 72 h after TM injection, liver tissues and plasma
samples were isolated for lipid analysis. (A–C) Oil-red O staining of lipid droplets in the livers of Ire1aHepfe/ and Ire1aHepfe/þ mice after
TM challenge for indicated time periods (magnification  200). (D) Transmission electron micrographs of liver tissue sections from Ire1aHepfe/
and Ire1aHepfe/þ mice at 24 h after TM injection (magnification:  3500). (E) Levels of plasma lipids in the Ire1aHepfe/ and Ire1aHepfe/þ mice
at 8 h after injection with TM or vehicle. Chol, total plasma cholesterol; TG, triglycerides; HDL, high-density lipoproteins; (V) LDL, low and
very low-density lipoproteins. Each bar denotes the mean±s.e.m. (n¼ 6 mice per group); *Po0.05. P-values are shown for statistically
significant differences. (F) Levels of liver cellular lipids in the Ire1aHepfe/ and Ire1aHepfe/þ mice at 8 h after injection with TM or vehicle. CE,
cholesterol ester; TG, triglycerides; FA, fatty acids; Chol, total liver cholesterol. Each bar denotes the mean±s.e.m. (n¼ 3 mice per group);
*Po0.05.
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from control Ire1aHepfe/þ mice injected with TM (Supple-
mentary Figure S2A). In contrast to TG, the levels of other
neutral lipids, including cholesterol esters (CE), FAs, and
cholesterol, were not significantly different between the livers
of Ire1aHepfe/ and Ire1aHepfe/þ mice, even after TM injection
(Figure 4F). Additionally, the liver content of phospholipids,
including phosphatidylethanolamine (PtdEtn), phosphatidyl-
choline (PtdCho), and sphingomyelin, were not significantly
affected by Ire1a deletion (Supplementary Figure S2B
and C). Consistent with this observation, expression levels of
phoshocholine cytidylyltransferase a (CCTa), the rate-limit-
ing enzyme in PtdCho biosynthesis, were comparable in the
livers from Ire1aHepfe/ and Ire1aHepfe/þ mice (Supple-
mentary Figure S2D). These findings suggest that the in-
creased liver TG accumulation observed upon Ire1a deletion
in hepatocytes was not due to any alteration in phospholipid
synthesis.
IRE1a represses expression of lipogenic transcriptional
activators upon ER stress
Hepatic lipid accumulation may be caused by different
metabolic perturbations: increased FA delivery, increased de
novo lipogenesis, decreased FA oxidation, or inadequate TG
secretion as VLDL (Musso et al, 2009). To understand the
molecular basis underlying the hepatic steatosis in Ire1a-null
livers, we analysed expression of genes that regulate lipid
biosynthesis, transport, storage, oxidation, as well as lipid
droplet formation. Through quantitative gene expression
analyses, we found that Ire1a deletion in hepatocytes
increased expression of three classes of lipogenic regulators
or enzymes that are essential for hepatic lipid deposition:
(1) transcription factors of the C/EBP family, peroxisome
proliferator-activated receptor g (PPARg), and their down-
stream targets; (2) adipose differentiation-related protein
(ADRP) and ER-associated fat-inducing transcripts (FITs);
and (3) key enzymes required for TG biosynthesis (Figure 5).
Originally identified as the master regulator of adipo-
genesis, the nuclear receptor PPARg has also been implicated
in hepatic steastosis (Gavrilova et al, 2003; Schadinger et al,
2005; Tontonoz and Spiegelman, 2008). The PPARg gene
encodes two isoforms, PPARg1 and PPARg2, that are differen-
tially expressed depending on the cell type and stress condi-
tions (Fajas et al, 1997; Vidal-Puig et al, 1997; Dubuquoy
et al, 2002; Yamazaki et al, 2010). Expression of the Pparg2
mRNA in the liver tissues of Ire1a-null and control mice was
barely detectable, either under non-stressed conditions or
after TM treatment (Supplementary Figure S3). In compa-
rison, the levels of Pparg1 mRNA were slightly increased in
the livers from Ire1aHepfe/ mice in the absence of TM
challenge, and this difference became statistically significant
after TM injection (Figure 5A). Additionally, other PPAR
isoforms, including PPARa and PPARd, were not significantly
affected by hepatocyte-specific Ire1a deletion (Figure 5A).
These results suggest that PPARg1 is the major PPAR isoform
that contributes to TM-induced hepatic steatosis. C/EBPb and
C/EBPd act upstream of PPARg by directly binding to the
PPARg promoter to induce its transcription (Wu et al, 1995,
1996; Tontonoz and Spiegelman, 2008). PPARg can induce
C/EBPa expression, and C/EBPa can itself bind to the
C/EBP site in the Pparg promoter, providing for a stable,
self-reinforcing regulatory loop. Compared with livers from
control Ire1aHepfe/þ mice, the livers from Ire1aHepfe/ mice
displayed increased expression of the C/ebpb and C/ebpd
mRNAs, and this increase became statistically significant
after TM treatment (Figure 5A). However, expression levels
of C/ebpa mRNA were modestly decreased in the Ire1a-null
livers, compared with that in the control livers, after TM
treatment for 8 h (Figure 5A). This is consistent with
the previous demonstration that ER stress downregulates
C/EBPa expression (Rutkowski et al, 2008; Sha et al, 2009).
Furthermore, expression levels of the mRNA encoding liver
X receptor a (LXRa) and carbohydrate responsive element
binding protein (ChREBP) were increased in livers from
Ire1aHepfe/ mice (Figure 5A), compared with that in the
control livers from Ire1aHepfe/þ mice. LXRa and ChREBP are
involved in the PPARg-regulated cascade and have important
roles in the induction of lipogenesis and hepatic steatosis
(Tontonoz and Spiegelman, 2008; Musso et al, 2009).
In addition to the upregulation of C/EBPb, C/EBPd,
and PPARg, hepatocyte-specific Ire1a deletion also increased
expression of key factors required for hepatic lipid droplet
formation, including ADRP and fat-inducing transcript 2
(FIT2) after TM injection, and other PPARg target lipogenic
genes, including aP2, Fat/Cd36, and Fsp27, in the liver tissue
in response to TM treatment (Jiang and Serrero, 1992;
Brasaemle et al, 1997; Kadereit et al, 2008; Matsusue et al,
2008; Musso et al, 2009) (Figure 5B and D; Supplementary
Figure S4). Moreover, we also examined expression of other
lipogenic genes upon hepatocyte-specific Ire1a deletion.
Expression of the mRNAs encoding key enzymes required
for de novo hepatic TG biosynthesis, including stearyl coen-
zyme A (CoA) desaturase 1 (SCD1), diacylglycerol acetyl-
transferase 1 (DGAT1), DGAT2, and acetyl CoA carboxylase 1,
was significantly increased in the Ire1a-null livers after TM
treatment (Figure 5B), which is consistent with the increased
hepatic lipid accumulation in the Ire1a-null livers after TM
treatment. Although transcriptional induction of the genes
encoding sterol regulatory element binding protein 1c
(SREBP1c), FA synthase (FASN), PPARa, PPARd, PGC-1a,
and PGC-1b was suppressed by TM treatment, there was
no significant difference in the expression of these genes
between Ire1aHepfe/ and Ire1aHepfe/þ mice, either in the
presence or absence of TM injection (Figure 5B and D;
Supplementary Figure S5). The gene expression correlated
with the lipogenic phenotype in TM-induced hepatic steato-
sis, as the protein levels of C/EBPb, C/EBPd, PPARg, and
ADRP were also increased in the Ire1aHepfe/ liver, compared
with the control, in response to TM challenge (Figure 5A–D).
Interestingly, in response to TM treatment, levels of SREBP1c
precursor, but not its cleaved and activated form, were
decreased in both Ire1a-null and control livers, while the
levels of cleaved/active SREBP1c were slightly increased in
the Ire1a-null liver after TM treatment (Figure 5D). Apparently,
under conditions of TM treatment, reduced expression of the
Srebp1c mRNA reflected levels of the SREBP1c precursor, but
not its mature/functional form (Supplementary Figure S5;
Figure 5D). The inconsistency between transcriptional induc-
tion of specific lipogenic genes and TM-induced lipogenesis
phenotype was further evidenced by induction of the genes
involved in FA oxidation or uptake. Expression of the genes
involved in FA oxidation, including Acox1, Cpt1a, and
Cyp4a10, and the genes involved in FA uptake/transport,
including Fatp2, Fat/Cd36, Fabp1, and Fabp4 (aP2), was
modestly increased in the Ire1aHepfe/ liver, compared
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with the control, after TM treatment (Musso et al, 2009)
(Supplementary Figure S4). However, our measurement of
radiolabelled acetate incorporation suggested no significant
difference in FA oxidation or uptake between the Ire1a-null
and control primary cultured hepatocytes (data not shown),
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Figure 5 IRE1a represses expression of key lipogenic regulators in the liver in response to ER stress. (A, B) Quantitative real-time RT–PCR
analysis of liver mRNA in Ire1aHepfe/ and Ire1aHepfe/þ mice. Total RNAs from the livers of Ire1aHepfe/ and Ire1aHepfe/þ mice at 3 months of age
at 8 h after injection with TM (2mg/g body weight) or vehicle (V) were subjected to quantitative real-time RT–PCR analysis. Expression values
were normalized to b-actin mRNA. Fold changes are shown relative to mRNA expression in one of the control (Ire1aHepfe/þ ) untreated mouse
livers. Each bar denotes the mean±s.e.m. (n¼ 6 mice per group); *Po0.05; **Po0.01. P-values are shown for statistically significant
differences. (C, D) Western blot analysis of liver tissue from Ire1aHepfe/ and Ire1aHepfe/þ mice at 8 h after injection with TM (2mg/g body
weight) or vehicle. Semiquantitative RT–PCR analysis was performed to measure the levels of spliced and unspliced Xbp1 mRNAs as an
indicator of IRE1a activity in the livers (C, bottom panel). In western blot analysis of C/EBPb, we detected the C/EBPb LAP (liver-enriched
transcriptional activator protein) isoform of about 35 kDa in the mouse liver tissue samples (Calkhoven et al, 2000). Because PPARg2 was not
detected at the mRNA level in the liver tissue in the absence or presence of TM challenge (A, B), the PPARg signals from the western blot
analysis likely reflected PPARg1. The experiments were repeated at least three times with consistent results, and representative data are shown.
The values below the gels represent protein signal intensities after normalization to that of a-tubulin.
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induction of specific lipid-associated genes in TM-induced
hepatic steatosis models.
Interpretation of studies from gene-deleted organisms is
always compromised by adaptive responses that may occur.
To test whether IRE1a is directly involved in regulating
expression of C/EBP family transcription factors under
conditions of acute ER stress, we overexpressed wild-type
or mutant forms of IRE1a in Ire1a-null hepatocytes.
Upon accumulation of unfolded protein in the ER, IRE1a is
activated through trans-auto-phosphorylation at Ser/Thr
residues to elicit its endoribonuclease (RNase) activity
(Schroder and Kaufman, 2005). Previously, we demonstrated
that Lys to Ala mutations that destroy IRE1a kinase activity
(K599A) or RNase activity (K907A) decrease Xbp1 mRNA
splicing, as well as expression of downstream UPR
target genes (Figure 6A) (Tirasophon et al, 1998; Zhang
et al, 2005). To understand how IRE1a regulates expression
of the lipogenic trans-activators C/EBPb and C/EBPd, we
expressed wild-type IRE1a, kinase mutant IRE1a (K599A),
RNase mutant (K907A) IRE1a, or spliced XBP1 by adenovirus
delivery to immortalized Ire1a-null hepatocytes. To verify
adenovirus-mediated expression, we examined Xbp1 mRNA
splicing in the hepatocytes infected with these adenoviruses.
In response to TM treatment, spliced Xbp1 mRNA was
not detected in the mock-infected Ire1a-null hepatocytes or
the hepatocytes infected with adenoviruses that express
K599A or K907A IRE1a mutant. In contrast, spliced Xbp1
mRNA was detected in control hepatocytes (Ire1afe/fe) that
harbour two floxed Ire1a alleles and Ire1a-null hepatocytes
(Ire1afe/Cre) infected with adenovirus that expresses wild-
type IRE1a or spliced Xbp1 (Figure 6B). Analysis of expres-
sion of C/EBP family members demonstrated that Ire1a-null
hepatocytes express higher levels of C/ebpb and C/ebpd
mRNAs than the control hepatocytes (Figure 6C and D),
consistent with the in vivo results (Figure 5A). Expression
of the K599A or K907A IRE1a mutant in the Ire1a-null
hepatocytes did not reduce C/ebpb mRNA expression and
only slightly reduced C/ebpd mRNA expression in response to
TM treatment (Figure 6C and D). In contrast, expression of
wild-type IRE1a in the Ire1a-null hepatocytes reduced both
C/ebpb and C/ebpd mRNA expression to the levels similar to
those observed in the control hepatocytes (Figure 6C and D),
suggesting a direct role for IRE1a in modulating expression of
C/ebpb and C/ebpd mRNAs in hepatocytes. Moreover, over-
expression of the product of IRE1a RNase, spliced XBP1,
failed to decrease levels of C/ebpb and C/ebpd mRNAs in
the Ire1a-null hepatocytes (Figure 6C and D). Taken together,
these data suggest that IRE1a can decrease C/ebpb and
C/ebpd mRNA levels in response to ER stress through mecha-
nisms involving its kinase and RNase activities. However,
overexpression of spliced Xbp1 mRNA, the target of IRE1a
RNase activity, did not reduce C/ebpb and C/ebpd mRNA
levels in the Ire1a-null hepatocytes (Figure 6C and D). This
suggests that IRE1a may downregulate C/EBPb and C/EBPd
expression through alternative mechanisms rather than
splicing of Xbp1 mRNA under conditions of ER stress.
IRE1a is required for efficient secretion of plasma lipids
Hepatocytes secrete apolipoprotein B (ApoB)-containing lipo-
protein particles (VLDL and LDL) that transport cholesterol
and FAs in the form of TGs to peripheral tissues (Shelness and
Sellers, 2001; Musso et al, 2009). Because Ire1aHepfe/ mice
exhibit decreased plasma lipids in the absence or presence of
ER stress compared with control mice (Figure 4E and F), we
asked whether IRE1a is required for efficient secretion of
lipoproteins into the plasma. To evaluate the involvement of
IRE1a in the secretion of apolipoproteins, we first examined
levels of ApoB in the liver and plasma samples from
Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice in
the presence or absence of TM treatment. Under the non-
stressed condition, disruption of IRE1a did not significantly
affect the levels of two ApoB isoforms, ApoB100 and ApoB48,
in murine liver and plasma samples (Figure 7A and B). At
24 h after TM injection, more hepatic ApoB was present while
less plasma ApoB was detected in Ire1a-null mice, compared
with that in the control mice (Figure 7A and B). This
observation suggests that IRE1a may be required for secretion
of ApoB-containing lipoproteins under conditions of ER
stress. To confirm this hypothesis, we analysed secretion
rates of ApoB in primary hepatocytes isolated from Ire1a-
null and control mice by pulse-label and pulse-chase experi-
ments. ApoB was immunoprecipitated from cell lysates and
media samples and analysed by SDS–polyacrylamide gel
electrophoresis followed by fluorography. The pulse-chase
experiments indicated that the secretion rates of both
ApoB100 and ApoB48 were comparable between Ire1a-null
and control hepatocytes under the non-stressed condition
(Figure 7C and D). However, after 6 h of TM treatment, the
secretion rates of ApoB48 were decreased in the Ire1a-null
hepatocytes, compared with that in the control hepatocytes
(Figure 7C and D). This observation is consistent with more
dramatic reduction of plasma ApoB in Ire1a-null mice than
the control mice when they were challenged with TM (Figure
7A and B). Moreover, in either Ire1a-null or control hepato-
cytes, we did not detect any significant levels of secreted
ApoB100 in response to TM treatment, supporting the TM-
mediated suppression of ApoB100 secretion suggested by
western blot analysis with the Ire1a-null and the control
mice (Figure 7A–D). Together, our observations suggest that
IRE1a is required for hepatocytes to efficiently secrete ApoB-
containing lipoproteins under conditions of ER stress.
IRE1a protects from non-TM stress-induced hepatic
steatosis
To further evaluate the role of IRE1a in preventing stress-
induced hepatic steatosis in the absence of TM, we induced
ER stress in the livers of Ire1a-null and control mice by
alternative mechanisms. First, we treated the mice with
the clinically relevant ER stress-inducing agent Bortezomib
(also known as Velcade or PS-341). Bortezomib is a highly
selective and reversible proteasome inhibitor that was
approved for treatment of multiple myeloma and is in more
extensive clinical trials for other solid tumour malignancies
(Richardson et al, 2003, 2006). Although the mechanisms
involved in its anti-cancer activity are still under investiga-
tion, Bortezomib was recently shown to activate the UPR
and ER stress-associated apoptosis by inhibiting the 26S
proteasome and ERAD (Lee et al, 2003a; Fribley et al, 2004;
Nawrocki et al, 2005; Fels et al, 2008). To test whether
Bortezomib can cause ER stress-associated hepatic steatosis
and whether IRE1a has a protective role in Bortezomib-
induced hepatic steatosis, we administered Bortezomib into
Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice
through tail-vein injection. Injection of Bortezomib induced
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Figure 6 Overexpression of IRE1a suppresses upregulation of CEBPb and CEBPd in Ire1a-null hepatocytes. (A) Depiction of domain structures
for wild-type and mutant versions of IRE1a protein. K599A, IRE1a kinase mutant; K907A, IRE1a RNase mutant. Ire1a-null or control
hepatocytes were infected with recombinant adenoviruses expressing different versions of IRE1a, spliced Xbp1 mRNA, or empty vector control.
The infected hepatocytes were then treated with TM (2 mg/ml) for the times indicated. (B) Semiquantitative RT–PCR analysis of spliced and
unspliced Xbp1 mRNAs in the Ire1a-null (Ire1afe/CRE) or control (Ire1afe/fe) hepatocytes. (C, D) Quantitative real-time RT–PCR analysis of
C/ebpb and C/ebpd mRNAs in adenovirus-infected hepatocytes. At 48 h after infection of Ire1a-null or control hepatocytes with the indicated
adenoviruses, the hepatocytes were treated with TM (5 mg/ml) for the times indicated. Expression values of C/ebpb and C/ebpd mRNAs were
normalized to b-actin mRNA. Fold changes of mRNA were measured by comparing to the expression level of mRNA in one of the empty virus-
transfected control cells. Hep ctl, control (Ire1afe/fe) hepatocytes; Ire1a/, Ire1a-null (Ire1afe/CRE) hepatocytes. A full-colour version of this
figure is available at The EMBO Journal Online.
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ER stress in the liver, as evidenced by increased expression of
spliced Xbp1 and Chop mRNAs in the liver of mice injected
with Bortezomib (Figure 8A). Particularly, the expression of
Chop mRNA in livers of the Ire1aHepfe/mice was significantly
greater than that of Ire1aHepfe/þ mice after Bortezomib treat-
ment. Spliced Xbp1 mRNA in the liver from Ire1aHepfe/ mice
was hardly detected (Figure 8A), reflecting the absence of
IRE1a. At 36 h after injection of Bortezomib, hepatic lipid
accumulation was observed in the livers of Ire1aHepfe/ and
control Ire1aHepfe/þ mice (Figure 8B). However, hepatic lipid
accumulation in the Ire1aHepfe/ mice was greater than that
observed in the Ire1aHepfe/þ mice. Direct measurement of
liver TG demonstrated that Bortezomib treatment increased
TG accumulation in the Ire1aHepfe/ mice, compared with the
Ire1aHepfe/þ mice (Figure 8C). The increase in TG accumula-
tion correlated with increased expression of key lipogenic
regulators, including C/EBPb, C/EBPd and PPARg, in the
livers of the Ire1aHepfe/ mice after Bortezomib treatment
(Figure 8D). Together, these observations suggest that
IRE1a is required to attenuate hepatic steatosis in response
to ER stress.
Hepatic lipid accumulation can cause lipotoxicity, repre-
sented by hepatocyte apoptosis, in the pathogenesis of fatty
liver disease (Jou et al, 2008; Malhi and Gores, 2008).
Consistent with this notion, increased expression of ER
stress-induced pro-apoptotic factor CHOP was observed in
the livers of the Ire1aHepfe/ mice (Figure 8A and D). TUNEL
staining demonstrated that the percentage of apoptotic cells
in the livers of Bortezomib-treated Ire1aHepfe/ mice was
increased approximately five times compared with that of
the Ire1aHepfe/þ mice (Supplementary Figure S6), suggesting
that IRE1a has an important role in preventing ER stress-
induced hepatic steatosis and apoptosis.
In addition to Bortezomib treatment, we utilized two
pathophysiologically relevant stress models, expression of a
human blood clotting factor VIII (hFVIII) that is prone to
misfolding and partial hepatectomy, to test the involvement
of IRE1a in stress-induced hepatic steatosis. Hydrodynamic
DNA tail-vein injection of hFVIII expression vectors was used
to direct expression of a misfolding-prone hFVIII in hepato-
cytes (Malhotra et al, 2008). In this study, the hFVIII is a
B-domain-deleted variant of hFVIII that is secreted as a
functional clotting factor. Analysis of this molecule is signi-
ficant because it has previously been used in human haemo-
philia A gene therapy studies directing FVIII expression to the
hepatocyte (Pierce et al, 2007). However, these approaches
have not produced physiologically significant levels of hFVIII
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Figure 7 IRE1a is required for efficient secretion of ApoB-containing apolipoproteins. (A, B) Western blot analysis of ApoB in the liver and
blood plasma samples from Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice at 24 h after injection with TM (2mg/g body weight) or
vehicle. Levels of fatty acid synthase in the liver tissues and albumin in the plasma were measured as internal controls. The values below the
gels represent the normalized protein signal intensities. FASN, fatty acid synthase; Alb, albumin. (C) Primary hepatocytes from Ire1a-null
(Ire1afe/) and control (Ire1afe/þ ) mice were labelled with [35S]methionine/cysteine for 25 min and then chased for the indicated times. For
TM-treated samples, the primary hepatocytes were treated with TM (10 mg/ml) for 6 h before and throughout the pulse-chase experiments.
Radiolabelled ApoB-containing apolipoproteins were immunoprecipitated from the cell lysates and the media with a rabbit anti-ApoB
polyclonal antibody, and resolved by 5% SDS–polyacrylamide gel electrophoresis with fluorography. The experiments were repeated at least
three times with consistent results, and representative data are shown. (D) Quantification of secretion rates of ApoB48- or ApoB100-containing
apolipoproteins from Ire1a-null (Ire1afe/) or control (Ire1afe/þ ) primary hepatocytes to culture media in the absence or presence of TM
treatment, as indicated in the panel (C). Secretion rates of ApoB¼ secreted ApoB48(100)/cellular ApoB48(100). Levels of secreted ApoB48(100)
were quantified based on the signals of ApoB48(100) present in the culture media, and levels of cellular ApoB48(100) were quantified based
on the signals of ApoB48(100) present in the cellular lysates of the Ire1a-null or control primary hepatocytes, as shown in the panel (C).
A full-colour version of this figure is available at The EMBO Journal Online.
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the UPR is activated in mice that express hFVIII (Malhotra
et al, 2008). Analysis of hFVIII secreted into the plasma
demonstrated that Ire1a deletion reduces the secretion effi-
ciency of hFVIII, with concomitant intracellular accumulation
of hFVIII antigen in the liver (Figure 8E), although the mRNA
expression for hFVIII was similar (Figure 8F). The decrease in
hFVIII was selective as there was no difference in plasma
albumin (Figure 7B). In support of the role of IRE1a in
preventing ER stress-induced hepatic steatosis, FVIII expres-
sion caused greater lipid accumulation in Ire1a-null mice,
compared with the control mice (Figure 8G). Moreover,
Ire1a-null mice produced less plasma TGs but more hepatic
TGs than the control mice after expression of hFVIII
(Figure 8H). Additionally, expression of key lipogenic
genes, including Dgat2, Acc1, Scd1, Adrp, and ChREBP, was
increased in the Ire1a-null mice upon expression of hFVIII
(Figure 8I).
The second pathophysiologic model we used to test the
role of IRE1a in hepatic lipid homeostasis was partial hepa-
tectomy, the surgical removal of liver (Fausto et al, 2006). In
the clinic, partial hepatectomies are performed for liver
transplantation or for surgical removal of carcinoma or
B
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Figure 8 Mice with hepatocyte-specific Ire1a deletion exhibit severe hepatic steatosis in response to Bortezomib treatment or expression of a
misfolding-prone hFVIII. (A–C) Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice at 3 months of age were injected with Bortezomib
(1 mg/g body weight) into the tail-vein. At 36 h after injection, the mice were fasted for 8 h prior to euthanasia and collection of samples.
(A) Quantitative real-time RT–PCR analysis for expression of Chop and spliced Xbp1 mRNAs in the liver. Expression values were normalized to
b-actin mRNA. Fold changes of mRNA levels were determined by comparison to the expression level in one of the controls. Each bar denotes
the mean±s.e.m. (n¼ 6 mice per group); *Po0.05; **Po0.01. BTZ, Bortezomib. (B) Frozen liver tissue sections stained with Oil-red O for
hepatic lipid contents after the Bortezomib treatment (magnification  400). (C) Levels of intracellular liver triglycerides after the Bortezomib
treatment. (D) Western blot analysis of C/EBPb, C/EBPd, PPARg, and CHOP in the liver. Levels of b-actin protein were included as internal
controls. The values below the gels represent normalized protein signal intensities. (E–I) Plasmid DNA vector (100mg/mouse) expressing an
hFVIII transgene encoding a misfolding-prone hFVIII (hFVIII) was transferred into the Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice
at 3 months of age through hydrodynamic tail-vein injection. Liver tissues and blood plasma samples were collected at 24 h after the injection.
(E) Levels of the hFVIII antigen in liver cellular lysates or plasma of Ire1a-null and control mice after the injection of the hFVIII expression
vector. Each bar denotes the mean level of hFVIII antigen in plasma (ng/ml) or in liver tissue (ng/mg liver protein)±s.e.m. (n¼ 3 mice per
group). *Po0.05. (F) Quantitative real-time RT–PCR analysis for expression of hFVIII mRNA in the liver of Ire1a-null and control mice after the
injection of the hFVIII expression vector. Expression values were normalized to b-actin mRNA. Fold changes of mRNA levels were determined
by comparison to the expression level in the uninjected control. Each bar denotes the mean±s.e.m. (n¼ 3 mice per group); **Po0.01. UI,
uninjected control. (G) Frozen liver tissue sections stained with Oil-red O for hepatic lipid contents after the injection of the expression
vector for hFVIII (magnification  400). (H) Levels of hepatic and plasma triglycerides in the mice after the injection of hFVIII expression
vector. (I) Quantitative real-time RT–PCR analysis for expression of lipogenic genes in the liver of Ire1a-null and control mice after the injection
of the hFVIII expression vector. Expression values were normalized to b-actin mRNA. Fold changes of mRNA levels were determined by
comparison to the expression level in one of the controls. Each bar denotes the mean±s.e.m. (n¼ 3 mice per group); **Po0.01.
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hepatoma tumours (Fausto, 2001). After partial hepatectomy,
the livers from Ire1a-null mice displayed profound steatosis,
as reflected by accumulation of hepatic lipid droplets and
increased hepatic TGs, compared with the control mice
(Supplementary Figure S7A and B). Taken together, these
additional non-TM pathophysiologic stress models further
confirmed that IRE1a has a critical role in preventing stress-
induced hepatic steatosis.
Discussion
Analysis of mice with hepatocyte-specific Ire1a deletion
demonstrated that IRE1a is essential to maintain hepatic
lipid homeostasis, especially under conditions of ER stress
(Supplementary Figure S8). Our findings show that (1) IRE1a
is required for the expression of genes that encode functions
critical for oxidative protein folding, protein transport from
the ER to the Golgi, and ERAD; (2) Ire1a deletion leads to
selective activation of ER stress-induced pro-apoptotic tran-
scription factors; (3) Ire1a deletion in hepatocytes causes
severe hepatic steatosis and hypolipidemia after ER stress
challenge; (4) IRE1a modulates lipogenesis by downregulat-
ing expression of C/EBPb, C/EBPd, PPARg, and key enzymes
for TG biosynthesis under conditions of ER stress; (5) IRE1a
is required for efficient secretion of ApoB-containing lipo-
proteins; and (6) IRE1a protects the liver from hepatostea-
tosis in response to Bortezomib treatment, expression of the
misfolding-prone hFVIII, or partial hepatectomy. These find-
ings indicate that the most evolutionarily conserved UPR
transducer IRE1a is required to repress lipid accumulation
in the liver, especially when protein-folding homeostasis is
disrupted in the ER.
Our studies demonstrate that deletion of Ire1a signi-
ficantly alters ER function. This was reflected by defective
induction of ER chaperones and enzymes that are required
for protein oxidative folding, ER-to-Golgi trafficking, and
ERAD (Figure 2). Importantly, Ire1a deletion led to selective
upregulation of the UPR-regulated pro-apoptotic transcription
factors ATF4, CHOP, and ATF3 in response to ER stress
(Figure 3A). Upon ER stress, induction of ATF4, CHOP,
and ATF3 is regulated by the PERK/eIF2a subpathway of
the UPR (Scheuner et al, 2001; Harding et al, 2003; Wek et al,
2006). Interestingly, the Ire1a-null livers expressed much
higher levels of ATF4, CHOP, and ATF3, compared with
the control livers, although there was no significant activa-
tion of the PERK/eIF2a pathway at the later time points of
ER stress treatment (Figure 3A–C). It is possible that elevated
GADD34 expression promotes dephosphorylation of eIF2a
and PERK after the longer periods of ER stress. At the
later time points after TM treatment, the levels of ATF4,
CHOP, and ATF3 proteins were diminished in control liver
tissue and isolated hepatocytes, while their levels remained
high in the Ire1a-null liver tissues and hepatocytes from
8 to 72 h after TM treatment (Figure 3A and E). Because
ATF4, CHOP, and ATF3 are ER stress-induced pro-apoptotic
factors, our data suggest that IRE1a is required for cells
or tissues to adapt to ER stress. This was further confirmed
by increased caspase-3 cleavage and positive TUNEL stain-
ing in the Ire1a-null livers after TM treatment (Figure 3A
and D).
Our findings suggest that IRE1a protects from hepato-
steatosis upon acute ER stress conditions through at least
two regulatory mechanisms (Supplementary Figure S8): (1)
IRE1a attenuates C/EBPb, C/EBPd, and PPARg transcriptional
control and (2) IRE1a is required for efficient secretion of
apolipoprotein. PPARg has two major isoforms, g1 and g2,
that are generated from the same gene by alterative RNA
splicing (Fajas et al, 1997; Vidal-Puig et al, 1997). PPARg2 is
highly expressed in adipose tissue and is upregulated in
steatotic livers of ob/ob mice, while PPARg1 is found at
low levels in many tissues, including fat and liver tissues
(Tontonoz et al, 1994; Dubuquoy et al, 2002; Schadinger et al,
2005; Zhang et al, 2006b; Musso et al, 2009; Yamazaki et al,
2010). It was proposed that both PPARg1 and PPARg2 con-
tribute to formation of fatty liver, although PPARg2 is more
effective in activating the transcription of adipogenic and
lipogenic genes than PPARg1 (Vidal-Puig et al, 1997;
Gavrilova et al, 2003; Matsusue et al, 2003; Zhang et al,
2004; Yamazaki et al, 2010). C/EBPb and C/EBPd induce
transcription of PPARg by directly binding to the PPARg
promoter (Wu et al, 1995, 1996; Tontonoz and Spiegelman,
2008). Our findings indicate that IRE1a is required to repress
expression of C/EBPb, C/EBPd, and PPARg1, but not PPARg2,
in hepatocytes in response to acute ER stress imposed by TM
treatment. In the absence of IRE1a, ER stress significantly
increased expression levels of C/EBPb, C/EBPd, and PPARg1
in the liver (Figure 5). Interestingly, our data suggest that
overexpression of wild-type IRE1a, but not spliced XBP1,
reduced expression of C/ebpb and C/ebpd mRNAs in the
Ire1a-null hepatocytes in response to ER stress (Figure 6C
and D). Therefore, it is possible that IRE1a prevents ER stress-
induced hepatic steatosis through transcriptional suppression
or degradation of the C/ebpb and C/ebpd mRNAs upon ER
stress. A recent study showed that C/EBPb can induce
expression of the Xbp1 mRNA and that spliced XBP1 directly
induces expression of C/EBPa during adipogenesis (Sha et al,
2009). Consistent with a role of spliced XBP1 in expression
of C/EBPa, expression of the C/ebpa mRNA was decreased
in the Ire1a-null livers in the presence or absence of TM
treatment (Figure 5A). Based on these observations, it is
also possible that the upregulation of C/EBPb and C/EBPd
in the Ire1a-null liver results from the feedback regulation
caused by decreased expression of C/EBP1a. If that is the
case, there may exist a regulatory loop in which IRE1a
modulates expression of C/EBP family transcription factors
under conditions of ER stress. Future studies are required to
explore the mechanism by which IRE1a regulates expression
of the mRNAs encoding the C/EBP transcription factor family
upon ER stress.
In the absence of TM challenge, Ire1a-null mice displayed
mild hepatic steatosis and decreased plasma lipids (Figure
4A, E, and F). Based on the microarray analysis, the expres-
sion of genes involved in the endomembrane protein secre-
tion machinery, including Sec61a1, Sec24d, and Tmed3, was
slightly decreased in the Ire1a-null liver under the non-
stressed condition (Table I). This may lead to accumulation
of hepatic lipids intracellularly, a possible cause of mild
hepatic steatosis in the Ire1a-null liver. Moreover, slight
increase in expression of lipogenic genes encoding C/EBPb,
C/EBPd, PPARg1, LXRa, ChREBP, ADRP, FIT1, FIT2, DGAT1,
and DGAT2 was observed in the liver of Ire1a-null mice under
the non-TM-treated condition (Figure 5A and B), which may
partially account for the mild steatosis in the Ire1a-null livers
under the basal condition.
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Our results show that upregulation of hepatic C/EBPb,
C/EBPd, and PPARg1 in the absence of IRE1a correlates
with increased expression of the ChREBP, Lxra, Adrp, Fit2,
Fsp27, aP2, and Fat/Cd36 genes, the targets of PPARg and/or
C/EBPb in lipogenesis and lipid storage, in response to ER
stress (Figures 5A and 8I). Consistent with the upregulation
of these lipogenic trans-activators, expression of the genes
encoding key enzymes required for TG biosynthesis and/or
lipid droplet formation, including DGAT1, DGAT2, and SCD1,
was significantly increased in the Ire1a-null livers after TM
treatment (Figure 5B). Interestingly, a recent study showed
that XBP1 positively regulates expression of the Scd1, Dgat2,
and Acc2 mRNAs in the livers of mice fed a high-fructose
diet (Lee et al, 2008). However, the requirement of IRE1a-
mediated Xbp1 mRNA splicing for TG synthesis was not
characterized in the study with conditional Xbp1-null mice.
Alternatively, it is possible that IRE1a has different roles in
regulating de novo lipogenesis under conditions of acute ER
stress versus chronic metabolic stress. This raises an inter-
esting possibility that hepatocytes may utilize the same ER
stress sensor to achieve different outcomes in lipogenesis
depending on the type and/or degree of the stress.
Assembly and secretion of ApoB-containing lipoproteins
from hepatocytes are crucial to maintain hepatic lipid home-
ostasis (Musso et al, 2009; Rutledge et al, 2010). Previous
studies implicated that ER stress and UPR components are
critically involved in ApoB protein biosynthesis, stability, and
secretion (Ota et al, 2008; Qiu et al, 2009; Rutledge et al,
2009). Our study showed that IRE1a is required for efficient
secretion of ApoB-containing lipoproteins from hepatocytes
to peripheral tissues (Figure 7). Secretion rates of ApoB
species in the primary hepatocytes from the Ire1a-null and
control mice were comparable under non-stressed conditions,
although levels of ApoB48 in Ire1a-null primary hepatocytes
were slightly higher than that in the control hepatocytes
(Figure 7C and D). In response to TM treatment, the secretion
rates of ApoB proteins were more greatly decreased in the
Ire1a-null hepatocytes, compared with that in the control
hepatocytes, which may partially account for the hepatic
steatosis and hypolipidemia in the hepatocyte-specific Ire1a-
null mice. Note that TM treatment suppressed the production
of the ApoB100 species in both cultured primary hepatocytes
and in mice in vivo. The mechanism by which TM suppresses
production of ApoB100, but not ApoB48, requires further
elucidated.
Hepatic lipid accumulation can be caused by an imbalance
of any of the pathways involved in FA and TG synthesis,
export, uptake, and/or oxidation. We suspect that the
accumulation of liver TG in the hepatocyte-specific Ire1a-
null mice might be due to metabolic alterations. For example,
excess diacylglycerol can be converted to TG (Leonardi
et al, 2009). Overexpression of spliced form of XBP1 was
previously associated with increased level and activity
of CCT, a rate-limiting enzyme in the biosynthesis of
PtdCho (Sriburi et al, 2004, 2007). However, Ire1a deletion
in hepatocytes did not significantly reduce production of
phospholipids, including PtdCho and PtdEtn, in the presence
or absence of ER stress (Supplementary Figure S2).
Therefore, accumulation of hepatic TGs in Ire1a-null livers
is unlikely due to impaired phospholipid metabolism.
Moreover, in addition to the increased lipogenesis and defec-
tive apolipoprotein secretion in the Ire1a-null livers that we
have identified, the accumulation of TGs and lipid droplets in
the absence of IRE1a may result from abnormal lipid droplet
assembly that occurs in the ER (Cases et al, 1998, 2001;
Wolins et al, 2006). For future studies, it will be important to
determine whether any ER-associated enzymes involved in
lipid droplet formation are regulated by IRE1a.
Bortezomib is the only FDA-approved proteasome inhibitor
that is used to treat patients with multiple myeloma
(Richardson et al, 2003, 2006). Although Bortezomib was
originally developed based on its ability to prevent activation
of NFkB, recent studies suggest that Bortezomib causes ER
stress, hepatosteatosis, and hepatoxicity (Lee et al, 2003a;
Rosinol et al, 2005; Fels et al, 2008; Hernandez-Espinosa et al,
2008; Rutkowski et al, 2008). Our studies show that hepato-
cyte-specific Ire1a-null mice develop severe hepatic steatosis
and apoptosis after Bortezomib treatment. Intravenous injec-
tion of Bortezomib caused ER stress in the liver, and IRE1a is
required to attenuate Bortezomib-induced hepatoteatosis and
apoptosis (Figure 8). Therefore, the regulation of hepatic lipid
homeostasis by IRE1a may exist under general conditions of
acute ER stress, not only TM treatment. In addition, two
additional non-TM pathophysiologic stress models, in vivo
expression of a misfolding-prone hFVIII and partial hepatect-
omy, also demonstrated that IRE1a is required to prevent ER
stress-induced hepatosteatosis (Figure 8E–I; Supplementary
Figure S7). Taken together, our findings provide novel in-
sights into hepatic lipid homeostasis that requires the UPR
transducer IRE1a. Therefore, interventions to modulate
IRE1a-mediated signalling may provide a therapeutic avenue




Chemicals were purchased from Sigma unless indicated otherwise.
Synthetic oligonucleotides were purchased from Integrated DNA
Technologies, Inc. (Coralville, IA). Antibodies against phosphory-
lated eIF2a, phosphorylated PERK, and phosphorylated JNK
proteins were purchased from Cell Signaling Technologies, Inc.
(Danvers, MA). Antibodies against ATF4, CHOP, ATF3, GADD34, C/
EBPa, C/EBPb, C/EBPd, and PPARg were purchased from Santa
Cruz Biotechnologies, Inc. (Santa Cruz, CA). Antibody against ATF6
was purchased from Imgenex Corp (San diego, CA). Antibodies
against GRP78/BiP and GRP94 were purchased from Stressgen (Ann
Arbor, MI). Antibody against a-tubulin was purchased from Sigma.
Antibody against SREBP1c was purchased from Thermo Scientific
(Rockford, IL). Bortezomib reagent of clinical quality was kindly
provided by Dr Joanne Wang at the Wayne State University School
of Medicine.
Generation of IRE1a conditional knockout mice
A targeting vector for conditional deletion that spans exons 16 and
17 of the Ire1a gene was constructed in pFlox vector (Figure 1A).
The region for deletion was 0.65 kb sequence that spans exons 16–
17 with flanking intron sequence of the Ire1a gene. After production
of chimeric mice and F1 progeny from selected targeted clones, ZP3-
Cre-recombinase expression in vivo was utilized to select progeny
with deletion of neomycin (Neo) gene cassette flanked by loxP sites,
but not the loxP-flanked Ire1a gene sequence. This yielded a strain
of mice with a loxP-flanked Ire1a gene allele (Ire1afe/fe) with
apparently undisrupted expression of the Ire1a gene. This strain of
mice allows deletion of the functional Ire1a gene allele through
crossing with transgenic mice expressing temporally controlled or
tissue-specific Cre recombinase. To increase the deletion efficiency
for the Ire1a gene allele, we cross the Ire1afe/fe mice with previously
established heterozygous Ire1a-null (Ire1aþ /) mice (Lee et al,
2002) to generate a mouse strain with a loxP-flanked Ire1a allele and
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an Ire1a-null allele (Ire1afe/) (Figure 1A). Three sets of PCR
amplifications were used for genotyping of Ire1a conditional null
mice: (1) for PCR amplification of the Ire1a floxed and wild-type
alleles, we used primer sequences: 50-CAGAGATGCTGAGTGAAGAC-30,
and 50-ACAGTGGTTCCTGTGAAGGT-30. The floxed allele generates a
241-bp band and the wild-type allele produces a 377-bp fragment;
(2) for PCR amplification of Neo gene cassette to identify the Ire1a-
null allele, we used primer sequences as previously described
(Lee et al, 2002); (3) for PCR amplification of the Cre transgene we
used primer sequences: 50-GCGGTCTGGCAGTAAAAACTATC-30, and
50-GTGAAACAGCATTGCTGT CAC TT-30.
GeneChip microarray and bioinformatics analysis
IRE1a conditional null (Ire1aHepfe/) or the control
(Ire1aHepfe/þ ) mice of 3 months old were injected intraperitoneally
with TM (2 mg/g body weight) or vehicle (150mM dextrose), and
liver tissue was isolated at 8 h after the injection. Total RNA was
purified from liver tissues and subjected to Affymetrix microarray
analysis. For each microarray replicate, 10 mg RNA was fragmented
and hybridized to Murine Genome 430.2 gene chips following
Affymetrix instructions. The microarray data were analysed using
several software packages. D-Chip (2008 Version) (http://www.
dchip.org) was used to normalize the data set (Li and Wong,
2001). The median intensity from all unnormalized array chips
varies from 93 to 179 with P call between 52.5–58.5%. The original
signals were scaled towards the median intensity array in the
group at the probe intensity level. Normalization was performed
using a normalization curve with invariant probe sets. GeneSpring
GX (Silicon Genetics, Redwood City, CA) was used to identify
differentially expressed genes and hierarchical clustering. ANOVA
was used to analyse the difference. The P-value cutoff was 0.05.
Since there are 45101 probes in the Affymetrix Mouse 430.2 chip,
the Benjamini and Hochberg false discovery rate was used for
multiple testing corrections. All the significant genes between two
groups were filtered with expression level based on 1.5-fold
changes. DAVID 2008 version software was used to functionally
analyse the differentially expressed gene annotations and their
related biological pathways (Dennis et al, 2003).
Transmission electron microscopy
Liver tissues were fixed with 1.25% formaldehyde, 2.5% glutaral-
dehyde, 0.03% picric acid in 100 mM sodium cacodylate buffer.
After washing with 100 mM sodium cacodylate buffer, tissues were
treated for 1 h with 1% osmium tetroxide and 1.5% potassium
ferrocyanide, and then 30 min with 0.5% uranyl acetate in 50 mM
maleate buffer, pH 5.2. After dehydration in ethanol, tissues were
treated for 1 h in propylenoxide and then embedded in Epon/
Araldite resin. Ultrathin sections were collected on EM grids and
observed by using a JEOL 1200EX transmission electron microscope
at an operating voltage of 60 kV.
Mouse plasma lipid profiling
Mice were fasted for 8 h prior to euthanization and collection of
blood samples. Levels of plasma lipids in the mice were determined
enzymatically using commercial kits (Roche Diagnostics Corpora-
tion). Approximately 120ml of mouse blood plasma was collected
and subjected to analyses using commercial kits for total cholesterol
(Roche cat #: 3 313 018), HDL (Roche cat #: 3 034 569), and
Triglyceride (Roche cat #: 3 034 658) (Allain et al, 1974; Stein,1994).
Levels of plasma LDL were calculated based on the formula:
LDL¼ total cholesterol–HDL–(TGs/5).
Measurement of liver cellular lipids
Lipids were extracted from B50 mg of liver using a modification of
the Bligh and Dyer procedure as previously described (Leonardi
et al, 2009). Mice were fasted for 8 h prior to euthanization and
sample collection. The amount of each major lipid class was
measured by flame-ionization thin layer chromatography. TGs,
cholesterol, and CEs were separated using hexane:ether (90/10,
v/v). Phospholipids were resolved using chloroform:methanol:ace-
tic acid:water (50/25/8/2, v/v/v/v). The lipids were identified by
co-migration with authentic standards and quantified by compar-
ison with known amounts of standard lipids. Additionally,
measurement of levels of liver cellular TGs was performed using
a TG assay kit according to the manufacturer’s instructions
(BioAssay Systems, ETGA-200). Briefly, B100 mg of fresh liver
was homogenized in 500 ml PBS and then centrifuged to remove the
tissue debris. The supernatant, including the fatty debris on top,
was transferred into a new tube, and then add another 500 ml
of 10% Triton-X100 in PBS was added for TG measurement using
the kit.
Generation of immortalized Ire1a-null hepatocytes and
recombinant adenoviral infection
Primary murine hepatocytes were isolated from mice harbouring
floxed homozygous Ire1a alleles using a standard protocol (Berry
et al, 1991), and were immortalized by SV40 Tantigen. Immortalized
hepatocytes were treated with adenovirus-Cre in order to delete
the floxed Ire1a exons. Recombinant adenoviruses for the over-
expression of flag-tagged IRE1a (wild type and its mutant forms
K599A and K907A) (Qiu et al, 2010) were kindly provided by
Dr Yong Liu (Institute for Nutritional Sciences, Shanghai, China)
and amplified using the AdEasy System (Stratagene). Adenovirus
expressing spliced XBP1 was kindly provided by Dr Umut Ozcan
(Harvard University) (Park et al, 2010). Recombinant adenovirus
expressing GFP was kindly provided by Dr Jiande Lin (University
of Michigan). The Ire1a-null and control hepatocytes at about
60% confluency were infected with adenoviruses expressing
IRE1a wild-type, its mutant forms, or spliced XBP1 at an MOI of
100 for 48 h before they were treated with TM at the indicated
concentrations.
ApoB western blot analysis with mouse liver and plasma
samples and ApoB pulse-chase experiments with mouse
primary hepatocytes
Liver tissue and blood plasma samples were isolated from Ire1a-
null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) mice in the absence or
presence of TM treatment (2mg/g body weight) for 8 h. To prepare
the samples for ApoB western blot analysis, the liver tissue samples
were diluted three times and the plasma samples were diluted five
times before they were denatured. The denatured samples were
resolved by 5% SDS–polyacrylamide gel electrophoresis, trans-
ferred onto 0.45mm PVDF membranes, and followed by the
incubation with a rabbit anti-ApoB polyclonal antibody (a kind gift
from Dr Zhouji Chen, Washington University). For the pulse-chase
experiments with mouse primary hepatocytes, livers from both
Ire1a-null (Ire1aHepfe/) and control (Ire1aHepfe/þ ) were first
perfused by HBSS supplemented with 8 mM HEPES (pH 7.35) and
1 mM sodium pyruvate followed by collagenase digestion. Hepato-
cytes were pelleted by centrifugation at 50 g for 2 min, washed three
times with DMEM media, and then seeded in the collagen-coated
plates with Williams E media. Cells were attached in the plates for
48 h before the pulse-chase experiments. Hepatocytes were labelled
with [35S]methionine/cysteine (140mCi/ml) for 25 min and chased
at the indicated times. For TM-treated samples, the cells were
treated with TM (10mg/ml) for 6 h before and throughout the pulse-
chase experiments. Labelled ApoB apolipoprotein complexes were
immunoprecipitated from the cell lysates and the media with the
anti-ApoB antibody, resolved by 5% SDS–PAGE gel, and exposed to
a phosphoimager screen.
Oil-red O staining
Frozen liver tissue sections were stained with Oil-red O for lipid
content according to the standard protocol. Briefly, frozen liver
tissue sections of 8 mm were air dried, and then fixed in formalin.
The fixed sections were rinsed with 60% isopropanol before they
were stained with freshly prepared Oil-red O solution for 15 min.
After Oil-red O staining, liver sections were rinsed again with 60%
isopropanol. Nuclei were lightly stained with alum haematoxylin 5.
TUNEL for apoptosis
To visualize the apoptotic events in the liver tissue sections
of Ire1a-null and control mice, we used a fluorescent TUNEL
staining kit (Clontech) to detect DNA fragmentation with the
paraffin-embedded tissue section slides according to the manu-
facture’s instruction (Zhang and Kaufman, 2008b). The apoptotic
cells exhibited green fluorescence using a standard fluores-
cein filter set (520±20 nm). The cells were also stained with
propidium iodide (PI), to identify all cells by strong red cyto-
plasmic fluorescence. The percentage of apoptotic cells was
determined by calculating the number of TUNEL-positive cells
divided by the number of PI-positive cells from five fields of
each slide.
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Hydrodynamic tail-vein injection and quantification of
hFVIII antigen
We expressed a misfolding-prone hFVIII (B domain-deleted of
human FVIII) that has a secretion defect like the wild-type hFVIII
in murine liver using hydrodynamic tail-vein injection (Malhotra
et al, 2008). Plasmid DNA samples (100mg) were diluted in 2.5 ml
lactated Ringer buffer and infused over 10 s into the tail-vein
as previously described (Miao et al, 2004). Retro-orbital blood
collection was performed at 24 h after injection for measurement
of hFVIII activity and antigen in the plasma (Miao et al, 2004).
The hFVIII antigen was quantified by using an anti-human FVIII
light-chain sandwich ELISA from Affinity Biologicals Inc. (Ancaster,
Canada).
Statistics
Experimental results are shown as mean±s.e.m. (for variation
between animals or experiments). The mean values for biochemical
data from the experimental groups were compared by a paired or
unpaired, two-tailed Student’s t-test. Statistical tests with Po0.05
were considered significant.
Supplementary data
Supplementary data are available at The EMBO Journal Online
(http://www.embojournal.org).
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